Abrocitinib In The Treatment Of Moderate to Severe Atopic Dermatitis Overview This study examined the efficacy and safety of abrocitinib, a treatment for moderate-to-severe atopic dermatitis (AD), specifically focusing on patients with allergic comorbidities. Data from phase 2b and phase 3 trials were analyzed, pooling information from patients who received abrocitinib or